Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366122 | 0.87 | PKM (0.45) | HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL3366091 | 0.78 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL6069012 | 0.76 | HCRTR1 (0.51) | HCRTR1HCRTR2RAB9AMAPTNPC1 | |
| SCHEMBL3369471 | 0.74 | HCRTR1 (0.54) | HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL3366137 | 0.74 | USP30 (0.47) | HCRTR1HCRTR2HSD11B1RAB9AMAPT | |
| SCHEMBL3368893 | 0.73 | HCRTR1 (0.62) | HCRTR1HCRTR2TP53 | |
| SCHEMBL6068831 | 0.72 | HCRTR1 (0.49) | HCRTR1HCRTR2RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3369474 | 0.72 | HCRTR1 (0.47) | HCRTR1HCRTR2RAB9ATP53MAPT | |
| SCHEMBL3367428 | 0.71 | HCRTR1 (0.55) | HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL3369687 | 0.70 | HCRTR1 (0.62) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532141-B1 | 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | GRUENENTHAL GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | HCRTR1 461/4885HCRTR2 146/4885HSD11B1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.